Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

NCT04797780 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

246

Enrollment

INDUSTRY

Sponsor class

Stopped As per Sponsor decision, the study was terminated.

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Tamibarotene
DRUG: Placebo
DRUG: Azacitidine

Sponsor

Syros Pharmaceuticals